Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
ConclusionIn patients with COVID-19 pneumonia, early treatment with lopinavir-ritonavir was associated with faster time to clinical improvement and/or virological clearance than darunavir-cobicistat. Future trials are warranted to confirm these findings. Trial registrationClinicalTrials.gov number, NCT04425382.
Source: PLoS One - Category: Biomedical Science Authors: Eman Zeyad I. Elmekaty Source Type: research
More News: Biomedical Science | COVID-19 | Electronic Medical Records (EMR) | Kaletra | Middle East Health | Norvir | Pandemics | Pneumonia | Prezista | Qatar Health | Statistics | Study | Virology